COMP <GO>
CGON vs CRSP // DIVIDEND YIELD & FCF PAYOUT SAFETY
CG Oncology Inc. (NASDAQ) VS. CRISPR Therapeutics AG (NASDAQ) • 15-METRIC TALLY: CGON 9
— CRSP 2
■ METRIC PARITY
LAST: $63.47 (-0.77%) • MKT CAP: $5.63B
dividend-safety
0.00%
LAST: $54.26 (+0.28%) • MKT CAP: $5.25B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGON VS. CRSP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CGON | CRSP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.80% | -30.60% | +9.80 | CGON | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.35% | -6.59% | +4.24 | CGON | /fcf-yield <GO> |
| Operating Margin | -12.10% | -60.00% | +47.90 | CGON | /operating-margins <GO> |
| Net Profit Margin | -10.20% | -60.00% | +49.80 | CGON | /net-margins <GO> |
| Revenue Growth (YoY) | 8.80% | -65.00% | +73.80 | CGON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 7.97 | +18.03 | CGON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | CGON | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.3 | 54.9 | -9.60 | CRSP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.12 | -0.05 | CRSP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 28.0x | -8.00 | CGON | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.63B | $5.25B | $379.5M | CGON | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CGON REV | CRSP REV | CGON GROSS % | CRSP GROSS % | CGON FCF | CRSP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $3.5M | — | — | -$132.5M | -$345.9M |
| FY 2024 | $0 | $37.3M | — | — | -$78.9M | -$144.7M |
| FY 2023 | $0 | $371.2M | — | — | -$45.7M | -$277.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGON // BETA 1.07
CRSP // BETA 1.12